{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-291448","form_type":"8-K","ticker":"CGEM","cik":"0001789972","company_name":"Cullinan Therapeutics, Inc.","filed_at":"2025-11-21T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.472901+00:00","generated_at":"2026-05-16T17:40:40.278779+00:00","sec_items":["1.02"],"event_type":"other_material","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Cullinan Therapeutics terminates exclusive MIT license for CLN-617; program abandoned","bullets":["Terminates Exclusive Patent License Agreement with MIT for CLN-617, effective Feb 18, 2026.","Decision based on not pursuing further development of CLN-617 cancer immunotherapy.","Company will return licensed patent rights for CLN-617 technology to MIT.","CLN-617 was an exclusive worldwide license for a cancer immunotherapy product."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-291448","json":"https://secwatch.observer/filing/0001193125-25-291448.json","markdown":"https://secwatch.observer/filing/0001193125-25-291448.md","text":"https://secwatch.observer/filing/0001193125-25-291448.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1789972/000119312525291448/0001193125-25-291448-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1789972/000119312525291448/cgem-20251118.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T17:40:40.278779+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}